Full Press Release Details
Alterity Therapeutics to Present
at MST Financial Webinar
AUSTRALIA AND SAN FRANCISCO, USA - 24 July 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or
"the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative
diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am
Details are listed below:
AUSTRALIA PARTICIPANTS:
UNITED STATES PARTICIPANTS:
Register for the Zoom webcast:
Registration is required and dial in details will be sent directly
Investors will have the opportunity to ask questions during
the call, at the conclusion of the presentation.
About Alterity Therapeutics Limited
Alterity Therapeutics is a
clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases.
The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated
in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable
chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San
Francisco, California, USA. For further information please visit the Company's website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.
Investor and Media Contacts: